A. Lüdtke

Adenosine binding sites at S-adenosylhomocysteine hydrolase are controlled by the NAD+/NADH ratio of the enzyme.

H. Osswald, S. Stoeva, D. Kloor, 2003, Biochemical pharmacology.

Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.

Wei Wu, H. Worman, H. Schmidt, 2007, The Journal of clinical endocrinology and metabolism.

Hepatic Steatosis in Dunnigan-Type Familial Partial Lipodystrophy

M. Taupitz, J. Genschel, H. Worman, 2005, The American Journal of Gastroenterology.

Long‐term treatment experience in a subject with Dunnigan‐type familial partial lipodystrophy: efficacy of rosiglitazone

J. Genschel, H. Worman, H. Mehnert, 2005, Diabetic medicine : a journal of the British Diabetic Association.

Salmonella osteomyelitis in an immunocompromized patient presenting as a primary lymphoma of the bone.

P. Hohenberger, P. Tunn, T. Schulze, 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand

H. Worman, H. Schmidt, A. Lüdtke, 2007, Journal of Medical Genetics.

Peroxisome Proliferator-Activated Receptor-γ C190S Mutation Causes Partial Lipodystrophy

Wei Wu, S. Zinn-Justin, H. Worman, 2007 .

Post‐mortem findings in Dunnigan‐type familial partial lipodystrophy

H. Worman, A. Lüdtke, H. Schmidt, 2010, Diabetic Medicine.